Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
Healthcare
$70.75 +2.45%
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
52W Low $29.18High $105.00
Volume 0.10M
Average 0.17M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$16.70M
FY 2025 · Annual
Net Income
-$13.72M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.49M | 7.59M | 5.6M | 13.01M | 9.9B |
| Selling, General & Admin | 2.63M | 2.95M | 3.23M | 3.16M | 6.8B |
| Operating Expenses | 9.13M | 10.54M | 8.83M | 16.16M | 16.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.13M) | (10.54M) | (8.83M) | (16.16M) | (16.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24.02K | 21.24K | 429.04K | 404.02K | 2.99M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 24.02K | 21.24K | 429.04K | 575.3K | 2.99M |
| Income Before Tax | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| EPS (Diluted) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| 12.47M | 12.72M | 14.51M | 11.44M | 7.41M | |
| 12.47M | 12.72M | 14.51M | 11.48M | 7.41M |
MNPR Earnings Waterfall · TTM
NASDAQ:MNPR · Revenue to Net Income
Key Ratios
EPS$-2.07
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-29.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$15.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.07, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 |
How much revenue does MNPR generate?
Monopar Therapeutics Inc. (MNPR) reported $0.00 of revenue in fiscal 2025.
Is MNPR profitable?
Monopar Therapeutics Inc. (MNPR) reported -$13.72M of net income.
Continue the stock analysis
Jump to another research area for this company.